BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines

BreezeBio（前身为GenEdit）宣布进行B轮融资以推进内部精准基因药物管道

• New therapeutics in development for autoimmune disease and oncology

• 正在开发的自身免疫疾病和肿瘤学新疗法

• Lead therapeutic BRZ-101 designed to restore immune tolerance in type 1 diabetes, advancing into IND-enabling studies

• 领先的治疗药物BRZ-101旨在恢复1型糖尿病的免疫耐受，正推进到IND启用研究

• Expanding platform capabilities for NanoGalaxy®, including targeted delivery for in vivo CAR

• 扩展NanoGalaxy®平台的功能，包括针对体内CAR的靶向递送

SOUTH SAN FRANCISCO, Calif., February 25, 2026-- BreezeBio, Inc., formerly known as GenEdit, today announced the close of $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s NanoGalaxy delivery platform. The new BreezeBio name reflects the company’s momentum in translating powerful delivery technologies into practical, scalable genetic medicines with curative potential..

加利福尼亚州南旧金山，2026年2月25日——BreezeBio, Inc.（前身为GenEdit）今天宣布完成6000万美元的B轮融资，以推进其首个内部治疗项目进入临床，并继续扩展公司的NanoGalaxy递送平台。新的BreezeBio名称体现了公司将强大的递送技术转化为具有治愈潜力的实用且可扩展的基因药物的发展势头。

“Now that we can deliver genetic payloads to the right cells with precision, we are building genetic medicines designed to make a real difference for patients,” said Kunwoo (Ryan) Lee, Ph.D., Chief Executive Officer of BreezeBio. “We’ve completed our transition from a delivery platform to a therapeutics company, and this financing allows us to advance our first internal programs toward the clinic while continuing to expand the reach of NanoGalaxy.”.

“现在我们可以精准地将基因载荷递送到正确的细胞，我们正在构建旨在为患者带来真正改变的基因药物，”BreezeBio首席执行官Kunwoo（Ryan）Lee博士说道。“我们已经完成了从递送平台到治疗公司的转型，此次融资使我们能够推进首个内部项目走向临床，同时继续扩大NanoGalaxy的应用范围。”

The company’s lead therapeutic candidate, BRZ-101, is a novel immune modulation therapy designed to restore tolerance in type 1 diabetes. The therapy delivers autoantigens encoded by mRNA and tolerogenic co-factors to antigen-presenting cells, which in turn present the antigens to T cells in the context of tolerance.

公司的主要治疗候选药物BRZ-101是一种新型的免疫调节疗法，旨在恢复1型糖尿病的耐受性。该疗法将由mRNA编码的自身抗原和耐受性共因子递送至抗原呈递细胞，这些细胞随后在耐受环境中将抗原呈递给T细胞。

The process induces antigen-specific regulatory T cells (Tregs) that block the autoimmune response precisely without affecting the functioning of the immune system. In preclinical testing, BRZ-101 induced antigen-specific immune tolerance in multiple models of autoimmune disease, including the NOD mouse model of diabetes, and was well tolerated in mice and non-human primates.

该过程诱导产生抗原特异性调节性T细胞（Tregs），它们能够精准阻断自身免疫反应，同时不影响免疫系统的正常功能。在临床前试验中，BRZ-101在多种自身免疫疾病模型中诱导了抗原特异性免疫耐受，包括糖尿病的NOD小鼠模型，并且在小鼠和非人灵长类动物中表现出良好的耐受性。

The company is advancing BRZ-101 into IND-enabling studies..

公司正在推进BRZ-101进入支持新药临床试验（IND）的研究。

“BreezeBio is solving one of the most significant challenges in gene therapy, targeted delivery, and in doing so is helping define the next generation of genetic medicines,” said Vincent Jeong, Managing Director at Yuanta Investment, manager of the Ministry of Health, and lead investor in the Series B financing.

“BreezeBio 正在解决基因治疗中一个最重要的挑战——靶向递送，同时也在帮助定义下一代基因药物，”元大投资的董事总经理 Vincent Jeong 表示，他同时也是卫生部的管理者，以及 B 轮融资的首席投资者。

“With platform validation through the company’s strategic collaboration and milestone achievement with a global biotech partner and clear progress toward clinical development, BreezeBio is approaching an important inflection point as it advances a differentiated internal pipeline designed to address significant unmet needs in autoimmune and other serious diseases.

“通过公司与全球生物技术合作伙伴的战略合作及里程碑式的成就进行平台验证，并在临床开发方面取得明确进展，BreezeBio正接近一个重要的转折点，推进一条差异化的内部管线，旨在满足自身免疫性疾病及其他严重疾病中显著未满足的需求。”

We believe BreezeBio is positioned to become a global genetic medicines developer, and Yuanta is committed to supporting that journey.”.

我们相信BreezeBio有望成为全球基因药物开发领域的佼佼者，元大证券将全力支持这一征程。"

The engine for BreezeBio’s therapeutic programs is the company’s proprietary NanoGalaxy platform, which has demonstrated targeted delivery to the immune, cardiac, pulmonary, and central nervous systems based on the physiochemical properties of the polymers that encapsulate the payloads and form the nanoparticles.

BreezeBio治疗项目的核心引擎是该公司专有的NanoGalaxy平台，该平台已证明能够基于封装有效载荷并形成纳米颗粒的聚合物的物理化学特性，实现对免疫、心脏、肺和中枢神经系统的靶向递送。

In addition, BreezeBio is expanding the platform with ligands conjugated to the nanoparticles for additional tissue and cell specificity, including delivery to T cells to enable in vivo CAR-T therapeutic development..

此外，BreezeBio 正在通过将配体与纳米颗粒结合来扩展该平台，以实现更多的组织和细胞特异性，包括递送到 T 细胞以推动体内 CAR-T 疗法的开发。

In parallel with its internal programs, BreezeBio continues to advance its multi-year collaboration and licensing agreement with Genentech, a member of the Roche Group. Following the initial milestone achievement and associated payment last year, R&D activities under the collaboration continue to progress..

与内部项目同步推进的同时，BreezeBio继续深化与罗氏集团成员Genentech的多年合作和许可协议。继去年达成初步里程碑并收到相关款项后，双方合作下的研发活动持续推进。

The Series B financing is led by new investors, Yuanta Investment and DSC Investment, with participation from SV investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, and others. Existing investors, including DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners also participated..

B轮融资由新投资者元大投资和DSC投资领投，SV投资、Kiwoom投资、STIC Ventures、Top Harvest Capital等参与。现有投资者DAYLI Partners、Pathway Investment、Loftyrock Investment、韩国投资伙伴、友利风险投资、KDB硅谷和ACVC Partners也参与了本轮融资。

About BreezeBio

关于BreezeBio

BreezeBio is a biotechnology company developing genetic medicines enabled by precise, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy® platform, BreezeBio engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system.

BreezeBio是一家生物技术公司，致力于开发通过精确的非病毒递送方式在生物相关组织中实现的基因药物。利用其专有的NanoGalaxy®平台，BreezeBio设计了能够将包括mRNA在内的基因载荷递送到特定细胞类型的纳米颗粒，并已证明可以成功递送到免疫细胞以及心脏、肺和中枢神经系统的特定组织。

The company is advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology, led by BRZ-101 to restore immune tolerance in type 1 diabetes. BreezeBio is headquartered in California in the South San Francisco area. For more information, visit www.breezebio.com..

公司正在推进一条专注于自身免疫疾病和肿瘤学的内部治疗管道，由BRZ-101主导，用于恢复1型糖尿病的免疫耐受。BreezeBio总部位于加利福尼亚州南旧金山地区。欲了解更多信息，请访问www.breezebio.com。

Contact:

联系：

Corporate: Kunwoo (Ryan) Lee, Ph.D., info@breezebio.com

公司：李坤宇（瑞安）博士，info@breezebio.com

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com

媒体：Jessica Yingling博士，Little Dog Communications Inc.，jessica@litldog.com